Crinone

Manufactured by Merck Group

Sourced in United Kingdom, Switzerland, Germany

Crinone is a medical device produced by Merck Group that is used for the administration of progesterone in gel form. It is designed to provide a controlled release of progesterone to support early pregnancy in certain medical conditions.

Automatically generated - may contain errors

Lab products found in correlation

Duphaston, by Abbott (11 mentions) Ovidrel, by Merck Group (5 mentions) Gonal f, by Merck Group (4 mentions) Cetrotide, by Merck Group (3 mentions) Progynova, by Bayer (3 mentions) Ovitrelle, by Merck Group (2 mentions) Estrofem, by Novo Nordisk (2 mentions) Femoston, by Abbott (2 mentions) 20 gauge ovum aspiration needles, by Cook Medical (1 mentions) Decapeptyl, by Ipsen (1 mentions) R hcg, by Merck Group (1 mentions) Ganirelix, by MSD (1 mentions) Decapeptyl, by Ferring (1 mentions) Cetrorelix, by Merck Group (1 mentions) Endometrin, by Ferring (1 mentions) Dydrogesterone tablets, by Abbott (1 mentions) Lutinus, by Ferring (1 mentions) Dydrogesterone, by Abbott (1 mentions) Menopur, by Ferring (1 mentions)

48 protocols using crinone

Endometrial Preparation Protocols for FET

Check if the same lab product or an alternative is used in the 5 most similar protocols

Two main schemes for endometrial preparation in this study were applied according to clinical judgment and patient preference. Natural cycle was performed for patients with regular menstrual cycle. Ovulation was confirmed by transvaginal ultrasonography and serum hormone measurement. On the day of ovulation, the patient received 90 mg vaginal progesterone (Crinone, Merck Serono, Germany) once daily. In artificial cycles, 6 mg oral estrogen (progynova, Bayer, Germany) daily was started on the second to fourth day of the menstrual cycle for one week and adjusted to 8–10 mg based on endometrial thickness and serum hormone levels. Vaginal progesterone (Crinone, Merck Serono, Germany) 90 mg daily and dydrogesterone (Duphaston, Abbott Biologicals B. V., Netherlands)10 mg twice daily were administered for endometrial transformation, as soon as the endometrial thickness reached ≥ 7 mm.
The blastocyst transfer was performed on the sixth day after ovulation confirmation or progesterone exposure using a soft-tipped Wallace (PortexLed., Hythe, United Kingdom) catheter under ultrasound guidance. All the patients received progesterone for luteal support and continued at the same doses until 14 days after FET and up to 10 weeks of gestational age in cases of pregnancy.

He Y., Tang Y., Liu H., Liu J, & Mao Y. (2023). No advantage of single day 6 good-quality blastocyst transfer versus single day 5 poor-quality blastocyst transfer in frozen-thawed cycles stratified by age: a retrospective study. BMC Pregnancy and Childbirth, 23, 79.

+ Open protocol

+ Expand

Standardized Ovarian Stimulation Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

All of the enrolled patients received a standardized individualized controlled ovarian stimulation protocol according to their BMI and ovarian reserve characteristics (i.e., female age, antral follicle count (AFC), basal follicle-stimulating hormone (FSH)), as previously described [24 (link)]. Final oocyte maturation was triggered with 5000 to 10,000 IU hCG (Livzon) when at least two leading follicles reached beyond 18 mm. Oocyte retrieval was performed transvaginally 36 ± 2 h after the hCG injection. Fertilization was performed by conventional insemination or ICSI 4–6 h after oocyte retrieval based on the sperm quality. Up to two day 3 embryos or day 5–6 blastocysts were transferred by specified gynecologists following standardized procedures.
On the day of oocyte retrieval, luteal-phase support was initiated with oral dydrogesterone (40 mg/day) (Duphaston, Abbott, Chicago, IL, USA) or vaginal progesterone (90 mg/day) (Crinone, Merck Serono, Darmstadt, Germany) until the tenth week of pregnancy.

Jiang H., Guo Y., Chen L., Shi H., Huang N., Chi H., Yang R., Long X, & Qiao J. (2023). Maternal Preconception Glucose Homeostasis and Insulin Resistance Are Associated with Singleton and Twin Birthweight of Neonates Conceived by PCOS Women Undergoing IVF/ICSI Cycles. Journal of Clinical Medicine, 12(11), 3863.

+ Open protocol

+ Expand

Luteal Phase Support for Pregnancy Outcomes

Check if the same lab product or an alternative is used in the 5 most similar protocols

From the day of oocyte retrieval, patients were given luteal support, 90 mg/d progesterone (Crinone, Serono) for patients in the VP group and 60 mg/d for IMP group. Until the 14^th day after embryo transfer, the serum hCG level was detected to determine pregnancy, wherein a serum hCG level ≥30 IU/ml referred to a biochemical pregnancy positive. Then, the patients were continuously administered luteal support until the 30^th day after embryo transfer and were subjected to B-ultrasound, wherein visible fetal sac referred to continuous pregnancy positive clinically. If the fetal sac was inside the uterus with fetal heartbeat, the patients were continuously provided luteal support until 10 weeks of intrauterine pregnancy, and then they were followed up by phone until delivery. However, if the fetal heartbeat was not detected, patients underwent an ultrasound review at an alternate week, wherein they might be diagnosed as spontaneous abortion, and were discontinued luteal support. Moreover, if the fetal heartbeat were detected, they would be given the treatment mentioned above. If the fetal sac was outside the uterus, patients were designated as ectopic pregnancy and discontinued luteal support, followed by surgical or conservative treatment.

Chi H.B., Liu N.N., Li R., Tao L.Y., Chen L.X, & Qiao J. (2018). Comparison of Vaginal Gel and Intramuscular Progesterone for In vitro Fertilization and Embryo Transfer with Gonadotropin-Releasing Hormone Antagonist Protocol. Chinese Medical Journal, 131(13), 1557-1561.

+ Open protocol

+ Expand

Mild Stimulation IVF: Optimizing Outcomes

Check if the same lab product or an alternative is used in the 5 most similar protocols

Controlled stimulation for IVF cycles was performed with a mild stimulation protocol using a combination of a gonadotropin-releasing hormone (GnRH) antagonist and gonadotropins. Patients received 150 IU of recombinant follicle-stimulating hormone (Gonal-F; Merck Serono, Darmstadt, Germany) alone as a daily injection from cycle day 3 until the day when human chorionic gonadotropin (hCG) was administered. The GnRH antagonist (Cetrotide, Merck Serono) was initiated on the day when the leading follicle reached a diameter of 14 mm. Ovarian follicular development was monitored by transvaginal ultrasonography. When the leading follicles reached ≥18 mm in maximum diameter, as detected by sonography, ovulation was induced by injecting 250 µg of hCG (Ovidrel, Merck Serono). Oocyte retrieval was performed using 20-gauge ovum aspiration needles (Cook Medical, Bloomington, IN, USA) under standard transvaginal ultrasound guidance 35–36 hours after hCG administration. The luteal phase was supported by progesterone injection or vaginal gel (Crinone, Merck Serono). A serum β-hCG test was performed about 2 weeks after oocyte retrieval. Clinical pregnancy was confirmed by the visualization of a gestational sac. Ongoing pregnancy was defined as a pregnancy that was maintained for over 20 weeks of gestation.

Chi H.J., Park J.S., Yoo C.S., Kwak S.J., Son H.J., Kim S.G., Sim C.H., Lee K.H, & Koo D.B. (2020). Effect of evaporation-induced osmotic changes in culture media in a dry-type incubator on clinical outcomes in in vitro fertilization-embryo transfer cycles. Clinical and Experimental Reproductive Medicine, 47(4), 284-292.

+ Open protocol

+ Expand

Blastocyst Transfer with Luteal Support

Check if the same lab product or an alternative is used in the 5 most similar protocols

On day 5 of embryo culture, women who are assigned to the fresh blastocyst transfer undergo a single blastocyst transfer. Luteal phase support with vaginal progesterone gel (Crinone, Merck Serono, Darmstadt, Germany) 90 mg/day and oral dydrogesterone 10 mg twice daily is started from the day of oocyte retrieval and continued until 12–15 days after embryo transfer when serum hCG is measured to determine pregnancy. If pregnancy is achieved, luteal phase support will be continued until 10 weeks’ gestation.

Wei D., Sun Y., Liu J., Liang X., Zhu Y., Shi Y, & Chen Z.J. (2017). Live birth after fresh versus frozen single blastocyst transfer (Frefro-blastocyst): study protocol for a randomized controlled trial. Trials, 18, 253.

+ Open protocol

+ Expand

Standardized Individualized COS Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Patients in this study received a standardized individualized controlled ovarian stimulation (COS) protocol according to ovarian reserve and other characteristics. All enrolled patients received GnRH agonist, GnRH antagonist, or minimal stimulation with clomiphene or letrozole [24 (link)]. When at least two dominant follicles reached ≥ 18 mm in diameter, ovulation was induced by injection of 5000 – 10,000 IU hCG (Livzon). Oocytes retrieval was performed transvaginally 36 ± 2 h after hCG administration. According to sperm quality, fertilization was performed by either conventional insemination or ICSI at 4 to 6 h after oocyte retrieval. Up to two day 3 embryos or day 5 – 6 blastocysts were transferred according to the Code of Practice for Assisted Reproductive Technology developed by the Ministry of Health of the People’s Republic of China by specified gynecologists with the same standard protocol.
Luteal-phase support was initiated on the day of oocyte retrieval with oral dydrogesterone (Duphaston, Abbott) at a daily dose of 40 mg or vaginal progesterone (Crinone, Merck Serono) at a daily dose of 90 mg until 10 weeks after conception.

Jiang H., Chen L., Huang N., Shi H., Chi H., Yang R., Long X, & Qiao J. (2023). Maternal preconception thyroid autoimmunity is associated with neonatal birth weight conceived by PCOS women undergoing their first in vitro fertilization/intracytoplasmic sperm injection. Journal of Ovarian Research, 16, 140.

+ Open protocol

+ Expand

Endometrial Preparation Protocols for IVF

Check if the same lab product or an alternative is used in the 5 most similar protocols

Three protocols were used for endometrial preparation: natural cycle, artificial cycle, and ovarian stimulation cycle. Vaginal progesterone (Crinone, Merck Serono, England), 90 mg once a day, was applied for luteal-phase support. The serum β-hCG test was performed 14 days after ET, and luteal-phase support was continued to the tenth week in the case of intrauterine pregnancy.

Wu Y., Ying Y., Cao M., Liu J, & Liu H. (2021). Trophectoderm biopsy of blastocysts for a preimplantation genetic test does not affect serum β-hCG levels in early pregnancy: a study using propensity score matching. Journal of Ovarian Research, 14, 78.

+ Open protocol

+ Expand

Luteal Support for Pregnancy

Check if the same lab product or an alternative is used in the 5 most similar protocols

Luteal support was provided by daily administration of vaginal progesterone gel (Crinone, Merck & Serono) at a dosage of 90 mg, along with a once-daily oral dose of 10 mg dydrogesterone(Duphaston, AbbottBiologicalsB.V) which was gradually tapered off after pregnancy and discontinued by the 12th week of gestation.

Zhang Y., Gong X., Zhang M., Zhu Y., Wang P., Wang Z., Liu C., La X, & Ding J. (2024). Establishment and validation of a nomogram for subsequent first-cycle live births in patients diagnosed with recurrent implantation failure: a population-based analysis. Frontiers in Endocrinology, 15, 1334599.

+ Open protocol

+ Expand

Controlled Ovarian Stimulation for IVF

Check if the same lab product or an alternative is used in the 5 most similar protocols

Patients received 0.1 mg triptorelin/S.C (Decapeptyl, Ipsen, Signes, France) daily for 2 weeks before anticipated menstruation. After pituitary downregulation was confirmed (indicated by serum E₂ levels <50 pg/mL and endometrial thickness <5 mm), the patients were administered Gonal-F with 0.05 mg/S.C triptorelin daily until oocyte maturation was triggered. For all the three protocols, if three follicles reached a mean diameter of 17 mm, 5000 IU of hCG (Lizhu, Zhuhai, China) was administered intramuscularly. Oocyte retrieval was performed 35–36 h after human chorionic gonadotropin (hCG) injection by transvaginal ultrasound-guided single-lumen needle aspiration. Intracytoplasmic sperm injection (ICSI) was performed only in severe male factor infertility or previous fertilization failure. Luteal phase support with 600 mg of micronized progesterone (Crinone, Merck Serono S.A., Switzerland) was initiated on day 1 after oocyte retrieval till the biopsy day.

Xu B., Wang J., Xia L., Zhang D., Wu X, & Zhang A. (2017). Increased Uterine NK cell numbers and perforin expression during the implantation phase in IVF Cycles with GnRH Antagonist Protocol. Scientific Reports, 7, 39912.

+ Open protocol

+ Expand

Embryo Grading and Transfer Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

On the third day after oocyte retrieval, the cleavage-stage embryos were graded by morphological criteria based on the number and size of blastomeres and the percentage of fragments [13 ]. No more than two embryos were transferred (usually one high-quality embryo and one non-high-quality embryo), while the remaining embryos were vitrified. Luteal phase support was provided by vaginal progesterone gel (Crinone, Merck Serono, Germany) 90 mg/day and dydrogesterone (Duphaston, Abbott Laboratories, IL, USA) 20 mg/day. If the patient was successfully impregnated, the luteal phase support would continue until 12 weeks of gestation.
All embryos were vitrified if the patient had a predisposition to ovarian hyperstimulation syndrome (OHSS), an unfavorable endometrium (endometrial thickness ≤ 6 mm or ≥ 16 mm), or progesterone levels ≥ 2 ng/ml on the day of hCG trigger. For frozen embryos transfer, the endometrium was prepared using a natural cycle protocol or an artificial cycle protocol, depending on the patient's condition.

Wang Y., Pang C., Wu H., Wei C., Yu Y., Xin X, & Lian F. (2023). The effect of large follicle puncture and aspiration on the outcomes of IVF-ET in patients with asynchronized follicles under the long GnRH-a protocol: a retrospective cohort study. BMC Pregnancy and Childbirth, 23, 64.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!